These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 38426642)

  • 1. Clinical relevance and therapeutic predictive ability of hypoxia biomarkers in head and neck cancer tumour models.
    Lee TW; Singleton DC; Harms JK; Lu M; McManaway SP; Lai A; Tercel M; Pruijn FB; Macann AMJ; Hunter FW; Wilson WR; Jamieson SMF
    Mol Oncol; 2024 Aug; 18(8):1885-1903. PubMed ID: 38426642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models.
    Harms JK; Lee TW; Wang T; Lai A; Kee D; Chaplin JM; McIvor NP; Hunter FW; Macann AMJ; Wilson WR; Jamieson SMF
    Cells; 2019 Jul; 8(7):. PubMed ID: 31337055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
    Jamieson SM; Tsai P; Kondratyev MK; Budhani P; Liu A; Senzer NN; Chiorean EG; Jalal SI; Nemunaitis JJ; Kee D; Shome A; Wong WW; Li D; Poonawala-Lohani N; Kakadia PM; Knowlton NS; Lynch CR; Hong CR; Lee TW; Grénman RA; Caporiccio L; McKee TD; Zaidi M; Butt S; Macann AM; McIvor NP; Chaplin JM; Hicks KO; Bohlander SK; Wouters BG; Hart CP; Print CG; Wilson WR; Curran MA; Hunter FW
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
    Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
    Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting HIF-1α/NOTCH1 pathway eliminates CD44
    Byun JY; Huang K; Lee JS; Huang W; Hu L; Zheng X; Tang X; Li F; Jo DG; Song X; Huang C
    Oncogene; 2022 Feb; 41(9):1352-1363. PubMed ID: 35013621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
    Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor.
    Gorur A; Patiño M; Shi T; Corrales G; Takahashi H; Rangel R; Gleber-Netto FO; Pickering C; Myers JN; Cata JP
    J Cell Physiol; 2021 Nov; 236(11):7698-7710. PubMed ID: 34038587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers.
    Peng S; Creighton CJ; Zhang Y; Sen B; Mazumdar T; Myers JN; Lai SY; Woolfson A; Lorenzi MV; Bell D; Williams MD; Johnson FM
    J Transl Med; 2013 Aug; 11():198. PubMed ID: 23981300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression.
    Liu W; Ding Z; Tao Y; Liu S; Jiang M; Yi F; Wang Z; Han Y; Zong H; Li D; Zhu Y; Xie Z; Sang S; Chen X; Miao M; Chen X; Lin W; Zhao Y; Zheng G; Zafereo M; Li G; Wu J; Zha X; Liu Y
    Mol Cancer; 2024 Jul; 23(1):141. PubMed ID: 38982480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus.
    Jiang Y; Cao W; Wu K; Qin X; Wang X; Li Y; Yu B; Zhang Z; Wang X; Yan M; Xu Q; Zhang J; Chen W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):365. PubMed ID: 31429766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens.
    Meneceur S; Löck S; Gudziol V; Hering S; Bütof R; Rehm M; Baumann M; Krause M; von Neubeck C
    Radiother Oncol; 2019 Aug; 137():24-31. PubMed ID: 31048234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Patient-Derived Xenografts to Explore the Efficacy of Treating Head-and-Neck Squamous Cell Carcinoma With Anlotinib.
    Hu F; Guo L; Yu J; Dai D; Xiong Y; He Y; Zhou W
    Pathol Oncol Res; 2021; 27():1610008. PubMed ID: 34955687
    [No Abstract]   [Full Text] [Related]  

  • 14. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
    Nytko KJ; Grgic I; Bender S; Ott J; Guckenberger M; Riesterer O; Pruschy M
    Oncotarget; 2017 Apr; 8(14):23702-23712. PubMed ID: 28423594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LOXL2-enriched small extracellular vesicles mediate hypoxia-induced premetastatic niche and indicates poor outcome of head and neck cancer.
    Zhu G; Wang L; Meng W; Lu S; Cao B; Liang X; He C; Hao Y; Du X; Wang X; Li L; Li L
    Theranostics; 2021; 11(19):9198-9216. PubMed ID: 34646366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma.
    Berggren KL; Restrepo Cruz S; Hixon MD; Cowan AT; Keysar SB; Craig S; James J; Barry M; Ozbun MA; Jimeno A; McCance DJ; Beswick EJ; Gan GN
    Oncogene; 2019 Nov; 38(48):7329-7341. PubMed ID: 31417185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
    Yun M; Choi AJ; Lee YC; Kong M; Sung JY; Kim SS; Eun YG
    J Exp Clin Cancer Res; 2018 Oct; 37(1):264. PubMed ID: 30376862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a rational strategy for integration of lactate dehydrogenase A suppression into therapeutic algorithms for head and neck cancer.
    Chen Y; Maniakas A; Tan L; Cui M; Le X; Niedzielski JS; Michel KA; Harlan CJ; Lu W; Henderson YC; Mohamed ASR; Lorenzi PL; Putluri N; Bankson JA; Sandulache VC; Lai SY
    Br J Cancer; 2021 May; 124(10):1670-1679. PubMed ID: 33742144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.
    Troost EG; Laverman P; Philippens ME; Lok J; van der Kogel AJ; Oyen WJ; Boerman OC; Kaanders JH; Bussink J
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1803-11. PubMed ID: 18421457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pescadillo ribosomal biogenesis factor 1 reduction suppresses tumour growth and renders chemosensitivity of head and neck squamous cell carcinoma.
    Li D; Yao C; Ding Z; Liu P; Chen X; Liu W; Yi F; Jiang C; Li H; Liu Y; Wu J
    Cancer Med; 2023 Mar; 12(5):5703-5717. PubMed ID: 36217758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.